Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Lung Cancer Clinical Trials in San Antonio | 145 Studies

Clinical Trials Lung CancerSan Antonio

Lung Cancer Clinical Trials in San Antonio

Find 145 clinical trials for lung cancer near San Antonio, Texas. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in San Antonio

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 101-120 of 145 trials

CompletedS9925: Collecting and Storing Samples From Patients With Lung CancerRATIONALE: Collecting and storing samples of tissue, blood, and sputum from patients with cancer to study in the laboratory may help the study of cancer in the future.NCT00920010·Mobile, Alabama and 430 others

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedAn Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) GeneThis is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with…NCT00932893·Little Rock, Arkansas and 263 others

CompletedA Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC.NCT03976362·Birmingham, Alabama and 177 others

TerminatedStudy of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerThis is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose…NCT03809624·Scottsdale, Arizona and 22 others

CompletedPhase 1 Dose Escalation Study for VIP236 in Patients With Advanced CancerDetermine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancerNCT05712889·Scottsdale, Arizona and 5 others

RecruitingA Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerThis is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer.NCT07227168·San Diego, California and 8 others

CompletedPhase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung CancerThis is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).NCT00630110·Scottsdale, Arizona and 35 others

TerminatedA Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of…NCT04504916·Hollywood, Florida and 13 others

TerminatedStudy of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to…NCT05226598·Colorado Springs, Colorado and 148 others

CompletedA Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatThe purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination…NCT02890069·Santa Monica, California and 24 others

RecruitingPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesBDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as…NCT05786924·Gilbert, Arizona and 48 others

Active not recruitingDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed…NCT05555732·Daphne, Alabama and 259 others

Active not recruitingStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with…NCT04380636·Mobile, Alabama and 204 others

CompletedA Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesThis is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of…NCT03629756·Scottsdale, Arizona and 14 others

RecruitingStudy of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with…NCT07349537·New Haven, Connecticut and 8 others

RecruitingA Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsThe goal of this clinical trial is to evaluate FMC-376 monotherapy and in combination with pembrolizumab in participants with advanced solid tumors with KRAS G12C mutations.NCT06244771·La Jolla, California and 25 others

SuspendedA Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.NCT05958199·Baltimore, Maryland and 6 others

Active not recruitingA First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsResearchers are looking for a better way to treat people who have advanced solid tumors.NCT05537740·Chicago, Illinois and 25 others

Active not recruitingA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other…NCT05355701·Fayetteville, Arkansas and 39 others

Active not recruitingGenetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery.NCT02194738·Birmingham, Alabama and 1659 others

PreviousPage 6 of 8Next

Other Conditions in San Antonio

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma